EP2832380B1 - Biologisch abbaubares material und verfahren zur herstellung von biologisch abbaubarem material - Google Patents

Biologisch abbaubares material und verfahren zur herstellung von biologisch abbaubarem material Download PDF

Info

Publication number
EP2832380B1
EP2832380B1 EP13768529.3A EP13768529A EP2832380B1 EP 2832380 B1 EP2832380 B1 EP 2832380B1 EP 13768529 A EP13768529 A EP 13768529A EP 2832380 B1 EP2832380 B1 EP 2832380B1
Authority
EP
European Patent Office
Prior art keywords
acid
group
multivalent compound
biodegradable material
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP13768529.3A
Other languages
English (en)
French (fr)
Other versions
EP2832380A4 (de
EP2832380A1 (de
Inventor
Masaki Fujita
Megumi Nakanishi
Kazuhiro Tanahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of EP2832380A1 publication Critical patent/EP2832380A1/de
Publication of EP2832380A4 publication Critical patent/EP2832380A4/de
Application granted granted Critical
Publication of EP2832380B1 publication Critical patent/EP2832380B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0042—Materials resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/668—Polyesters containing oxygen in the form of ether groups derived from polycarboxylic acids and polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/02—Polyesters derived from dicarboxylic acids and dihydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/02—Polyesters derived from dicarboxylic acids and dihydroxy compounds
    • C08L67/025—Polyesters derived from dicarboxylic acids and dihydroxy compounds containing polyether sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/36—Materials or treatment for tissue regeneration for embolization or occlusion, e.g. vaso-occlusive compositions or devices
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L101/00—Compositions of unspecified macromolecular compounds
    • C08L101/16—Compositions of unspecified macromolecular compounds the macromolecular compounds being biodegradable

Definitions

  • the present invention relates to a biodegradable material and a process of producing a biodegradable material.
  • Such polymer particles for embolization of blood vessels and the like are used in the form of spherical particles so as to tightly and securely embolize the blood vessels and the like.
  • the particles are delivered to a target site in a blood vessel or the like through a microcatheter with a small diameter or the like, there were problems such as an occurrence of clogging within the catheter due to insufficient flexibility of the polymer particles or aggregation between the particles, or irreversible deformation of the particles before their reaching to the target site.
  • an in situ gel represented by a gel composed of a copolymer such as poly(ethylene glycol/polylactic acid), and poly glycolic acid and the like (patent document 10), or a gel composed of dextran and poly N-isopropyl acrylamide (patent document 11); or a binary gel represented by a gel composed of polyethylene glycol and the like and a polycarboxy polysaccharide (patent document 12), a gel composed of 2 types of polyethylene glycols and the like (patent document 13), or an ion-crosslinked gel such as carboxymethyl chitosan (patent document 14), for example, is used as a biodegradable material such as an anti-adhesive material, a wound dressing material, a hemostatic material or a urinary incontinence-preventing material.
  • a biodegradable material such as an anti-adhesive material, a wound dressing material, a hemostatic material or a urinary incontinence-preventing material.
  • a poly(ethylene glycol/propylene glycol) copolymer (patent document 15), a poly(lactic acid/dioxanone) copolymer (patent document 16), a poly(ethylene glycol/modified amino acid/unmodified amino acid) copolymer (patent document 17), a poly(lactic acid/depsipeptide/ethylene glycol) copolymer (patent document 18), a porous sheet composed of a poly(lactic acid/ethylene glycol) copolymer (patent document 19) or the like is also used as a biodegradable material such as an anti-adhesive material, a wound dressing material, a hemostatic material or a urinary incontinence-preventing material; and attempts to control the biodegradability and flexibility thereof have been made.
  • US2008-0260802 A1 discloses a method of making a medical device by preparing a biodegradable material by cross-linking two biocompatible precursors.
  • a cross-linked material is formed by reacting in equimolar amounts an amine functional compounds having four amine groups with a carboxyl-functional compound having four carboxyl groups.
  • biodegradable materials composed of binary gels, for example, had a problem that their physical properties might be altered depending upon the environmental factors (such as temperature, humidity, or pH) or their blend ratio at the target site.
  • environmental factors such as temperature, humidity, or pH
  • biodegradable material located thereon may be deformed irreversibly.
  • an object of the present invention is to provide a biodegradable material having an enhanced shape recovery rate after deformation of the material and an improved flexibility.
  • the present invention provides the biodegradable material as described in the (1) to (12) below.
  • the biodegradable material of the present invention has an improved flexibility and an enhanced shape recovery rate after deformation of the material, and it can be suitably used as a vascular embolization material since it can be easily delivered to a target site in a blood vessel or the like without clogging inside a catheter, for example, and allows for an efficient embolization of the target site.
  • the biodegradable material of the present invention has an improved tensile strength and shear strength and is capable of recovering its shape after tensile deformation or shear deformation, it can be suitably used as an anti-adhesive material, a wound dressing material, a hemostatic material or a urinary incontinence-preventing material, which is used, for example, pasted on an organ or surrounding tissue that constantly keeps expanding and contracting.
  • the biodegradable material of the present invention is characterized by being a chemically cross-linked product between a multivalent compound A having 3 or more functional groups X selected from the group consisting of hydroxyl group, thiol group and amino group; and a multivalent compound B having 3 or more functional groups Y selected from the group consisting of carboxyl group, isocyanate group and thioisocyanate group wherein chemical cross-linkage(s) is/are formed by condensation reaction of the functional group(s) X and the functional group(s) Y; wherein the value of (y + z)/(x + z) is 1.2 to 4.0 when MA > MB, and the value of (x + z)/(y + z) is 1.2 to 4.0 when MA ⁇ MB; wherein x represents the number of the functional group(s) X which is/are not condensed with the functional group(s) Y; y represents the number of the functional group(s) Y which is/are not condensed with the
  • biodegradable refers to a property of a biodegradable material to be degraded, dissolved, absorbed or metabolized in a living body or to be excreted from inside to the outside of the body.
  • degradation reactions include hydrolysis and enzyme degradation. Hydrolysis is preferred because it does not depend on enzymes.
  • the term "chemical cross-linking" refers to binding of multivalent compound A and multivalent compound B using a cross-linker.
  • bonds include ester bonds, thioester bonds, amide bonds and the like. Ester bonds are preferred because the biodegradability of the biodegradable material will be increased.
  • the cross-linker is preferably a dehydration condensation agent. A state of being “chemically cross-linked” can be confirmed if no change in the appearance of the biodegradable material is observed after immersing the material in water at a temperature of 25°C for 1 hour.
  • multivalent compound A examples include:
  • Multivalent compound A has 3 or more functional groups X selected from the group consisting of hydroxyl group, thiol group and amino group.
  • Derivatives corresponding to multivalent compound A such as acid halides, esters, acid anhydrides and hydrochlorides are also included in multivalent compound A.
  • the "water soluble polymer” is preferably a polyalkylene glycol polymer such as PEG or PPG; a polyhydroxyalkyl (meth)acrylate polymer such as PVA, polyhydroxyethyl methacrylate or polyhydroxyethyl acrylate; or a cellulose polymer such as carboxymethyl cellulose, hydroxymethyl cellulose or hydroxyethyl cellulose; more preferably, a polyalkylene glycol polymer.
  • multivalent compound A is preferably a branched compound such as a branched polymer (branched polymer a1) formed by binding all of hydroxyl groups of a polyol with a homopolymer or a copolymer of a monomer(s) of a water-soluble polymer(s) selected from the group consisting of PEG and PPG, more preferably a copolymer of the branched polymer and a hydroxycarboxylic acid(s) (hydroxycarboxylic acid a2), even more preferably, a block copolymer wherein the hydroxycarboxylic acid(s) is/are bound to the end(s) of the branched polymer.
  • the polyol is preferably glycerin, polyglycerin or a monosaccharide such as pentaerythritol.
  • multivalent compound B examples include:
  • Multivalent compound B has 3 or more functional groups Y selected from the group consisting of carboxyl group, isocyanate group and thioisocyanate group.
  • Derivatives corresponding to multivalent compound B such as acid halides, esters and acid anhydrides are also included in multivalent compound B.
  • a dicarboxylic acid such as oxalic acid, malonic acid, succinic acid, fumaric acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, malic acid, tartaric acid or dodecane dioic acid; or citric acid is preferred for their ease of availability.
  • Succinic acid which exists in a living body and is highly safe, is more preferred.
  • Multivalent compound B is preferably a branched compound such as a compound formed by binding a hydroxyl group(s) of a branched polymer (branched polymer b1) formed by binding all of hydroxyl groups of a polyol with a homopolymer or a copolymer of a monomer(s) of a water-soluble polymer(s) selected from the group consisting of PEG and PPG, with a polycarboxylic acid(s) (polycarboxylic acid b2).
  • the polyol is preferably glycerin, polyglycerin or a monosaccharide such as pentaerythritol.
  • multivalent compound A and multivalent compound B are branched compounds, they preferably have a degree of branching of from 3 to 16, more preferably from 4 to 12. While too low a degree of branching results in a failure to improve the chemical cross-linking density and to provide sufficient strength of the biodegradable material, too high a degree of branching may hinder the chemical cross-linking reaction due to steric hindrance.
  • hydroxycarboxylic acid examples include glycolic acid, lactic acid, glyceric acid, hydroxybutyric acid, malic acid, tartaric acid, hydroxyvaleric acid, 3-hydroxyhexanoic acid and 6-hydroxycaproic acid.
  • cyclic compound composed of hydroxycarboxylic acid examples include, glycolide which is a cyclic dimer of glycolic acid, lactide which is a cyclic dimer of lactic acid and ⁇ -caprolactone which corresponds to 6-hydroxycaproic acid.
  • Examples of the copolymer formed by copolymerization of hydroxycarboxylic acids include, copolymers of lactic acid and glycolic acid, copolymers of lactic acid and terephthalic acid, copolymers of lactic acid and isophthalic acid, copolymers of 6-hydroxycaproic acid and glycolic acid, and copolymers of 6-hydroxycaproic acid and polybutylene succinate (copolymers of 1,4-butanediol and succinic acid).
  • the hydroxycarboxylic acid is preferably lactic acid.
  • the weight ratio and the like of a specific structure in each of multivalent compound A and multivalent compound B can be calculated based on the measurement results obtained by proton nuclear magnetic resonance method (hereinafter referred to as " 1 H-NMR"), under the following conditions.
  • 1 H-NMR proton nuclear magnetic resonance method
  • the hydrogen atom of the methine group at the ⁇ -position is characteristic (chemical shift value: about 5.2 ppm).
  • the hydrogen atom of the methylene group at the ⁇ -position is characteristic (chemical shift value: about 2.3 ppm).
  • the hydrogen atom of the methylene group at the ⁇ -position is characteristic (chemical shift value: about 4.8 ppm).
  • the 4 hydrogen atoms of the ethylene group are characteristic (chemical shift value: about 3.5 ppm).
  • Each weight ratio can be calculated based on the integral value of the signal appearing in each of these characteristic chemical shifts of the hydrogen atoms.
  • the complex elastic modulus thereof is preferably from 40 to 400 kPa.
  • the complex elastic modulus can be calculated based on the measurement results obtained by a viscoelasticity measuring apparatus (hereinafter referred to as a "rheometer") under the following conditions. Specifically, specified amounts of multivalent compound A and multivalent compound B (both as 0.3g/mL acetonitrile solutions) as well as a catalyst (0.1 g/mL acetonitrile solution) and a stock solution of condensation agent are quickly mixed to provide a mixed solution. A 500 ⁇ L quantity of the mixed solution was then dropped onto the apparatus plate, inserting the mixed solution between the fixture and the apparatus plate, and the dynamic viscoelasticity test was performed 105 s after the compounding.
  • a viscoelasticity measuring apparatus hereinafter referred to as a "rheometer”
  • acetonitrile-containing film refers to a film formed by chemically cross-linking multivalent compound A and multivalent compound B, with acetonitrile still contained, which film is obtained after the measurement by a rheometer.
  • complex elastic modulus is an index representing the flexibility of the biodegradable material, and refers to the value of the modulus E* (kPa) calculated by Equation 1 below, which value includes all of the elastic properties and the viscous properties of the sample to be measured, which is a viscoelastic body.
  • E* the modulus E* (kPa) calculated by Equation 1 below.
  • too low a value of the complex elastic modulus results in a failure to maintain the shape of the biodegradable material and to produce a desired embolization effect; whereas too high a value of the complex elastic modulus increases the resistance of the biodegradable material while passing through a catheter or the like.
  • the biodegradable material of the present invention is used as an anti-adhesive material, a wound dressing material, a hemostatic material, a urinary incontinence-preventing material or the like
  • too low a value of the complex elastic modulus results in a failure to maintain the shape of the biodegradable material and to produce a desired anti-adhesive effect on an organ or surrounding tissue
  • too high a value of the complex elastic modulus causes an excessive load to the vibrational motion of the organ or surrounding tissue.
  • the complex elastic modulus of the acetonitrile-containing film at a constant strain of 0.1% and a constant angular frequency of 10 rad/s is preferably from 40 to 400 kPa, more preferably, from 100 to 300 kPa.
  • E * E ⁇ + iE ⁇
  • the term "storage modulus” herein refers to the component in phase with the applied strain (the real part of the complex elastic modulus), of the complex elastic modulus measured when the viscoelastic body is infinitesimally deformed at a constant strain and a constant angular frequency, and is an index representing the elastic properties of the sample to be measured.
  • the storage modulus of the acetonitrile-containing film at a constant strain of 0.1% and a constant angular frequency of 10 rad/s is preferably from 40 to 400 kPa, more preferably, from 100 to 300 kPa.
  • the term “loss modulus” refers to the component in opposite phase with the applied strain only by ⁇ /2 (the imaginary part of the complex elastic modulus), and is an index representing the viscous properties of the sample to be measured.
  • gelation time which is the time required for the biodegradable material to gel.
  • the gelation time of the acetonitrile-containing film at a constant strain of 0.1% and a constant angular frequency of 10 rad/s is preferably from 100 to 1000 s, more preferably from 200 to 800 s.
  • the "loss tangent" herein is an index representing the flexibility of the biodegradable material and the ability of the deformed acetonitrile-containing film to recover its original shape, and corresponds to the value, tan ⁇ , calculated by Equation 2 below.
  • water-saturated state refers to a state where, when approximately 20 mg of the biodegradable film was immersed in 10 mL of phosphate buffered saline at 37 °C (while a test tube as a container was rotated using a rotator at a rate of 0.5 rotation/second to shake the content), the water content of the biodegradable film has become constant.
  • the expression "the water content is constant” refers to a state where, when the weight of the biodegradable film immersed in phosphate buffered saline at 37 °C was measured every minute, the rate of weight change with time thereof has become 10% or less.
  • the rate of weight change with time is the value Rw (%) calculated by Equation 3 below.
  • Rw W t ⁇ W t ⁇ 1 / W t ⁇ 100
  • the term “water content” refers to the value Wr (%) calculated by Equation 4 below.
  • the “biodegradable film in the dry state” herein refers to a biodegradable film which was immersed in deionized water at 25 °C for 3 hours and then vacuum dried at 25 °C for 12 hours.
  • the “biodegradable film in the water-saturated state” refers to a biodegradable film which was subjected to centrifugation (25°C, 1000 g ⁇ 5 minutes) after its water content had become constant to remove phosphate buffered saline. The water content of the biodegradable film is increased by infiltration of water into the film.
  • the 50% compressive load of the biodegradable film in the water-saturated state can be measured using a micro-strength evaluation tester, under the following conditions. Specifically, a load (changing) is applied to each biodegradable film described above to measure the load required to compress the film to 50% of the original film thickness.
  • recovery rate refers to the ability of the biodegradable material released from compression to recover its original shape before the compression, for example, after passing through a catheter with a small inner diameter. Specifically, it is an index representing the recovery rate of the original shape.
  • the recovery rate of the biodegradable film in the water-saturated state at a compression rate of 50% is preferably 70% or more, more preferably, 75% or more, because too low a recovery rate causes the biodegradable material to pass through the target site in the blood vessel to be embolized, for example, and to flow further downstream.
  • the recovery rate of the biodegradable film in the water-saturated state at a compression rate of 50% is measured using the same micro-strength evaluation tester as in the compression test under the following conditions, and corresponds to the value Rr (%) calculated by Equations 5 to 7 below. Specifically, a load (changing) is applied to the biodegradable film up to the 50% compressive load (i.e., the maximum test force, a compression rate of 50%) obtained by the compression test, and the load is then removed to the minimum test force.
  • the 50% compressive load i.e., the maximum test force, a compression rate of 50%
  • compression rate refers to the ratio of the film thickness of the biodegradable film after compression to the original film thickness, and corresponds to the value Cr (%) calculated by Equation 8 below.
  • Cr L 1 / d ⁇ 100 d: average thickness of the biodegradable film (mm)
  • the biodegradable material of the present invention is suitably used as a vascular embolization material. It is also suitably used as an anti-adhesive material, a wound dressing material, a hemostatic material, a urinary incontinence-preventing material or the like.
  • biodegradable particles can be used as they are, or used as a dispersion liquid in a suitable contrast medium or in a dispersion medium.
  • suitable contrast medium examples include water-soluble contrast media such as iopamidol injection, ioxaglic acid injection and iohexol injection; and oily contrast media such as iodized poppy oil. Water-soluble contrast media are preferred.
  • the dispersion medium examples include aqueous injection solutions and vegetable oils such as sesame oil and corn oil, containing a dispersant such as a polyoxysorbitan fatty acid ester, preservative such as methylparaben, or isotonic agent such as sodium chloride.
  • a dispersant such as a polyoxysorbitan fatty acid ester, preservative such as methylparaben, or isotonic agent such as sodium chloride.
  • the above mentioned vascular embolization material may further contain an antiseptic, stabilizer, solubilizer, excipient, and/or an effective component such as an antitumor agent.
  • the process of producing the biodegradable material of the present invention comprises a chemical cross-linking step wherein a multivalent compound A having 3 or more functional groups X selected from the group consisting of hydroxyl group, thiol group and amino group, and a multivalent compound B having 3 or more functional groups Y selected from the group consisting of carboxyl group, isocyanate group and thioisocyanate group, are dissolved in a solvent to allow chemical cross-linking reaction to proceed such that the value of NB/NA is 1.2 to 4.0 when MA > MB, and the value of NA/NB is 1.2 to 4.0 when MA ⁇ MB; wherein NA represents the total number of the functional groups X; NB represents the total number of the functional groups Y; MA represents the weight average molecular weight of the multivalent compound A; and MB represents the weight average molecular weight of the multivalent compound B, to obtain the biodegradable material.
  • Examples of multivalent compound A include a block copolymer of branched polymer a1 formed by binding all of hydroxyl groups of a polyol with PEG or PPG, and hydroxycarboxylic acid a2.
  • Examples of branched polymer a1 include 4-branched PEG (PTE series; manufactured by NiGK Corporation) and 8-branched PEG (HGEO series; manufactured by NiGK Corporation).
  • hydroxycarboxylic acid a2 is lactic acid, 6-hydroxycaproic acid, glycolic acid or the like
  • condensation polymerization is preferred as the process of producing multivalent compound A, which is a block copolymer of branched polymer a1 and hydroxycarboxylic acid a2.
  • hydroxycarboxylic acid a2 is a cyclic compound such as lactide, ⁇ -caprolactone or glycolide
  • ring-opening polymerization is preferred.
  • reaction solvent for the condensation polymerization a good solvent for branched polymer a1 such as 4-branched PEG or 8-branched PEG and hydroxycarboxylic acid a2 is used. Examples include dichloromethane, chloroform, acetonitrile and tetrahydrofuran, and mixed solvents thereof.
  • the reaction temperature is preferably set such that the good solvent employed refluxes.
  • the reaction pressure may be a reduced pressure, but normal pressure is preferred for ease of operation.
  • the reaction time is preferably from 2 to 48 hours, more preferably 4 to 24 hours, in order to appropriately control the molecular weight of the resulting multivalent compound A.
  • the total concentration of branched polymer a1 and hydroxycarboxylic acid a2 in the condensation polymerization varies depending on the types and the like of a1 and a2 used, and is preferably from 10 to 100% by weight, more preferably from 50 to 100% by weight.
  • the concentration of the catalyst in the reaction solvent is preferably from 0.01 to 0.5% by weight, more preferably from 0.1 to 0.3% by weight, since too high a concentration complicates the removal of the catalyst after the reaction while too low a concentration hinders the reaction.
  • reaction solvent for the ring-opening polymerization the same good solvent as for the condensation polymerization may be used. In order to increase the reactivity, however, it is preferable not to use the reaction solvent and to set the reaction temperature to 90 °C to 150 °C, more preferably to 100°C to 130 °C.
  • the reaction pressure may be a reduced pressure, but normal pressure is preferred for ease of operation.
  • the reaction time is preferably from 2 to 48 hours, more preferably 4 to 24 hours, in order to appropriately control the molecular weight of the resulting multivalent compound A.
  • the catalyst examples include metal catalysts.
  • the metal catalyst include metal alkoxides, metal halides, organic carboxylic acid salts, carbonic acid salts, sulfuric acid salts and oxides of tin, titanium, lead, zinc, cobalt, iron, lithium or a rare earth. In terms of polymerization reactivity, tin compounds are preferred.
  • tin compound examples include tin powder, tin(II) chloride, tin(IV) chloride, tin(II) bromide, tin(IV) bromide, ethoxytin(II), t-butoxytin(IV), isopropoxytin(IV), tin(II) acetate, tin(IV) acetate, tin(II) octylate, tin(II) laurate, tin(II) myristate, tin(II) palmitate, tin(II) stearate, tin(II) oleate, tin(II) linoleate, tin(II) acetylacetonate, tin(II) oxalate, tin(II) lactate, tin(II) tartrate, tin(II) pyrophosphate, tin(II
  • multivalent compound B examples include a branched compound formed by binding a branched polymer b1 formed by binding all of hydroxyl groups of a polyol with PEG or PPG, with a polycarboxylic acid b2.
  • branched polymer b1 examples include 4-branched PEG and 8-branched PEG.
  • polycarboxylic acid a2 may first be reacted with an electrophilic halogenating agent such as thionyl chloride or oxalyl chloride to be converted to a derivative such as an acid halide, acid anhydride or ester, which may then be subjected to condensation reaction to provide multivalent compound B.
  • an electrophilic halogenating agent such as thionyl chloride or oxalyl chloride
  • dehydration condensation agent examples include carbodiimide compounds such as N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (hereinafter referred to as "EDC"), 1,3-bis(2,2-dimethyl-1,3-dioxolane-4-ylmethyl)carbodiimide, N- ⁇ 3-(dimethylamino)propyl- ⁇ -N'-ethylcarbodiimide, N- ⁇ 3-(dimethylamino)propyl- ⁇ -N'-ethylcarbodiimide methiodide, N-tert-butyl-N'-ethylcarbodiimide, N-cyclohexyl-N'
  • the dehydration condensation agent may be used with a dehydration condensation accelerator.
  • the dehydration condensation accelerator include pyridine, 4-dimethylamino pyridine (hereinafter referred to as "DMAP"), triethylamine, isopropyl amine, 1-hydroxybenzotriazol and N-hydroxysuccinic acid imide.
  • reaction solvent for the condensation reaction of branched polymer b1 and polycarboxylic acid b2 a good solvent for b1 and b2 is used.
  • examples include dichloromethane, chloroform, acetonitrile and tetrahydrofuran, and mixed solvents thereof.
  • the reaction temperature is preferably set such that the good solvent employed refluxes.
  • the reaction pressure may be a reduced pressure, but normal pressure is preferred for ease of operation.
  • the reaction time is preferably from 2 to 48 hours, more preferably 4 to 24 hours, in order to appropriately control the molecular weight of the resulting multivalent compound B.
  • the total concentration of branched polymer b1 and polycarboxylic acid b2 in the condensation reaction varies depending on the types and the like of b1 and b2 used, and is preferably from 10 to 100% by weight, more preferably from 20 to 80% by weight.
  • the concentration of the catalyst in the reaction solvent is preferably from 0.01 to 0.5% by weight, more preferably from 0.1 to 0.3% by weight, since too high a concentration complicates the removal of the catalyst after the reaction while too low a concentration hinders the reaction.
  • Examples of the catalyst include pyridine, DMAP, triethylamine and isopropyl amine. Pyridine is preferred for ease of removal.
  • the fractional precipitation is a method in which obtained multivalent compound A or multivalent compound B is dissolved in a good solvent, and the resulting solution is added dropwise to a poor solvent under stirring to obtain purified multivalent compound A or multivalent compound B as a precipitate.
  • good solvent herein refers to an organic solvent in which the above multivalent compound A or multivalent compound B can be dissolved
  • poor solvent refers to an organic solvent in which the above multivalent compound A or multivalent compound B cannot be dissolved.
  • Examples of the good solvent used in the fractional precipitation include dichloromethane, chloroform, acetonitrile and tetrahydrofuran, and mixed solvents thereof.
  • the amount of the good solvent used varies depending on the composition and the like of the obtained multivalent compound A or multivalent compound B, and the concentration of the dissolved multivalent compound A or multivalent compound B is preferably from 10 to 80% by weight, more preferably from 20 to 70% by weight.
  • Examples of the poor solvent used in the fractional precipitation include alcohol organic solvents such as methanol and ethanol; ether organic solvents such as dimethyl ether, ethyl methyl ether and diethyl ether; hydrocarbon organic solvents such as pentane, hexane, heptane and octane; and mixed solvents thereof.
  • the amount of the poor solvent used also varies depending on the composition and the like of the obtained multivalent compound A or multivalent compound B. It is preferably from 50 to 1000% by weight, more preferably from 100 to 500% by weight relative to the good solvent.
  • multivalent compound A or multivalent compound B is dissolved in dichloromethane and the resulting solution is added dropwise to diethyl ether under stirring.
  • the obtained purified product is preferably washed with a poor solvent, more preferably, washed 2 to 5 times.
  • a protic solvent such as water or alcohol
  • the solvent used in the chemical cross-linking step an aprotic polar organic solvent with a dielectric constant of from 35 to 50 is preferred.
  • N,N-dimethylformamide hereinafter referred to as "DMF”
  • N,N-dimethyl acetamide N,N-dimethyl acetamide
  • acetonitrile is more preferred for ease of removal by evaporation under reduced pressure.
  • the dehydration condensation agent may be used with a dehydration condensation accelerator.
  • the dehydration condensation accelerator include pyridine, DMAP, triethylamine, isopropyl amine, 1-hydroxybenzotriazole, N-hydroxysuccinic acid imide and the like. DMAP is preferred for high reactivity and ease of removal after reaction.
  • Examples of the process of producing the biodegradable material of the present invention as a biodegradable film include a process in which multivalent compound A and multivalent compound B dissolved in an aprotic polar organic solvent with a dielectric constant of from 35 to 50 are introduced in a poor solvent, and chemical cross-linking reaction is then allowed to proceed while removing the aprotic polar organic solvent.
  • the poor solvent used to obtain the biodegradable film include oils such as synthetic oils and natural oils. Natural oils are more preferred.
  • Examples of the synthetic oil include silicone oils.
  • Examples of the natural oil include cottonseed oil, corn oil, coconut oil, olive oil, palm oil, rapeseed oil, safflower oil, sesame oil, soybean oil, sunflower oil, turpentine oil, almond oil, avocado oil, bergamot oil, castor oil, cedar oil, chlorophyll oil, clove oil, croton oil, eucalyptus oil, fennel oil, fusel oil, grape seed oil, jojoba oil, kukui nut oil, lavender oil, lemon oil, linseed oil, macadamia nut oil, meadowfoam oil, orange oil, origanum oil, persic oil and rose hip oil.
  • Cottonseed oil, corn oil, olive oil, rapeseed oil, safflower oil, sesame oil, soybean oil, or sunflower oil is preferred for its high biological safety and stable availability.
  • the obtained crude multivalent compound A1 was added dropwise to 100 mL of diethyl ether, and the resulting precipitate and the liquid component separating from diethyl ether were collected. These were then washed three times with 50 mL of diethyl ether to give purified multivalent compound A1.
  • the weight average molecular weight of the purified multivalent compound A1 as measured by GPC method was 15,400.
  • the obtained crude multivalent compound B1 was added dropwise to 100 mL of diethyl ether, and the resulting precipitate and the liquid component separating from diethyl ether were collected. These were then washed three times with 50 mL of diethyl ether to give purified multivalent compound B1.
  • the weight average molecular weight of the purified multivalent compound B1 as measured by GPC method was 5,800.
  • the obtained purified multivalent compound A1 and purified multivalent compound B1 were dried under reduced pressure, and each of these were dissolved in dehydrated acetonitrile (manufactured by Wako Pure Chemical Industries, Ltd.) to a concentration of 0.3 g/mL, respectively, to obtain solutions 1 and 2.
  • solution 1, solution 2, solution 3, DMAP/acetonitrile solution and EDC stock solution having the same concentration as the above-described biodegradable film 1 were mixed at the same volume ratio to obtain acetonitrile-containing film 1.
  • Biodegradable film 2 and acetonitrile-containing film 2 were evaluated in the same manner as in Example 1. The results are shown in Table 1.
  • biodegradable film 2 had a high compressive load and a high recovery rate.
  • Acetonitrile-containing film 2 had a high complex elastic modulus, and a short gelation time.
  • Example 2 The same operation as in Example 1 was carried out except that the amount of solution 1 was changed to 0.399 mL, the amount of solution 2 was changed to 0.601 mL, the amount of DMAP solution was changed to 0.030 mL, and the amount of EDC was changed to 0.053 mL, to obtain biodegradable film 3 and acetonitrile-containing film 3.
  • Biodegradable film 3 and acetonitrile-containing film 3 were evaluated in the same manner as in Example 1. The results are shown in Table 1.
  • biodegradable film 3 had a high compressive load and a high recovery rate.
  • Acetonitrile-containing film 3 had a high complex elastic modulus, and a short gelation time.
  • Example 2 The same operation as in Example 1 was carried out except that 8-branched PEG (SUNBRIGHT (registered trademark) HGEO5000; manufactured by NiGK Corporation) was used instead of multivalent compound A1 to obtain solution 3.
  • Biodegradable film 4 and acetonitrile-containing film 4 were evaluated in the same manner as in Example 1. The results are shown in Table 1.
  • Example 2 The same operation as in Example 1 was carried out except that 22.0 g of lactide was changed to 30.0 g of glycolide (PURASORB G; manufactured by Purac Biomaterials), and the amount of the tin octylate solution was changed to 1.28 mL, to obtain multivalent compound A2.
  • the weight average molecular weight of multivalent compound A2 as measured by GPC method was 14,100.
  • Example 1 The same operation as in Example 1 was carried out except that multivalent compound A2 was used instead of multivalent compound A1 to obtain solution 4.
  • Example 2 The same operation as in Example 1 was carried out except that 0.689 mL of solution 1 was changed to 0.670 mL of solution 4, the amount of solution 2 was changed to 0.330 mL, the amount of DMAP solution was changed to 0.017 mL, and the amount of EDC was changed to 0.029 mL, to obtain biodegradable film 5 and acetonitrile-containing film 5.
  • Biodegradable film 5 and acetonitrile-containing film 5 were evaluated in the same manner as in Example 1. The results are shown in Table 1.
  • biodegradable film 5 had a high compressive load and a high recovery rate.
  • Acetonitrile-containing film 5 had a high complex elastic modulus, and a short gelation time.
  • Example 2 The same operation as in Example 1 was carried out except that 10.0 g of branched polymer a1 was changed to 4-branched PEG (SUNBRIGHT (registered trademark) PTE 10000; manufactured by NiGK Corporation) to obtain purified multivalent compound A3.
  • the weight average molecular weight of the purified multivalent compound A3 as measured by GPC method was 20,500.
  • Example 1 The same operation as in Example 1 was carried out except that 10.0 g of branched polymer b1 was changed to 4-branched PEG (SUNBRIGHT (registered trademark) PTE10000; manufactured by NiGK Corporation) to obtain purified multivalent compound B2.
  • the weight average molecular weight of the purified multivalent compound B2 as measured by GPC method was 10,800.
  • Example 1 The same operation as in Example 1 was carried out except that purified multivalent compound A3 was used instead of purified multivalent compound A1 to obtain solution 5. The same operation as in Example 1 was carried out except that purified multivalent compound B2 was used instead of purified multivalent compound B1 to obtain solution 6.
  • Example 2 The same operation as in Example 1 was carried out except that 0.689 mL of solution 1 was changed to 0.487 mL of solution 5, 0.311 mL of solution 2 was changed to 0.513 mL of solution 6, the amount of DMAP solution was changed to 0.014 mL, and the amount of EDC was changed to 0.024 mL, to obtain biodegradable film 6 and acetonitrile-containing film 6.
  • Example 2 The same operation as in Example 1 was carried out except that 10.0 g of branched polymer a1 was changed to 8-branched PEG (SUNBRIGHT (registered trademark) HGEO10000; manufactured by NiGK Corporation) to obtain purified multivalent compound A4.
  • the weight average molecular weight of the purified multivalent compound A4 as measured by GPC method was 18,600.
  • Example 1 The same operation as in Example 1 was carried out except that 10.0 g of branched polymer b1 was changed to 8-branched PEG (SUNBRIGHT (registered trademark) HGEO10000; manufactured by NiGK Corporation) to obtain purified multivalent compound B3.
  • the weight average molecular weight of the purified multivalent compound B3 as measured by GPC method was 10,800.
  • Example 2 The same operation as in Example 1 was carried out except that 0.589 mL of solution 1 was changed to 0.589 mL of solution 7, 0.311 mL of solution 2 was changed to 0.411 mL of solution 8, the amount of DMAP solution was changed to 0.011 mL, and the amount of EDC was changed to 0.019 mL, to obtain biodegradable film 7 and acetonitrile-containing film 7.
  • Biodegradable film 7 and acetonitrile-containing film 7 were evaluated in the same manner as in Example 1. The results are shown in Table 1.
  • Biodegradable film 8 and acetonitrile-containing film 8 were evaluated in the same manner as in Example 1. The results are shown in Table 1.
  • biodegradable film 8 had a high compressive load and a high recovery rate.
  • Acetonitrile-containing film 8 had a high complex elastic modulus, and a short gelation time.
  • Example 2 The same operation as in Example 1 was carried out except that 0.689 mL of solution 1 was changed to 0.301 mL of solution 7, 0.311 mL of solution 2 was changed to 0.699 mL of solution 8, the amount of DMAP solution was changed to 0.019 mL, and the amount of EDC was changed to 0.033 mL, to obtain biodegradable film 9 and acetonitrile-containing film 9.
  • Biodegradable film 9 and acetonitrile-containing film 9 were evaluated in the same manner as in Example 1. The results are shown in Table 1.
  • biodegradable film 9 had a high compressive load and a high recovery rate.
  • Acetonitrile-containing film 9 had a high complex elastic modulus, and a short gelation time.
  • Example 2 The same operation as in Example 1 was carried out except that 22.0 g of lactide was changed to 20.0 g of ⁇ -caprolactone (manufactured by Wako Pure Chemical Industries, Ltd.), and the amount of tin octylate solution was changed to 0.94 mL, to obtain purified multivalent compound A5.
  • the weight average molecular weight of the purified multivalent compound A5 as measured by GPC method was 13,600.
  • Example 2 The same operation as in Example 1 was carried out except that the amount of solution 1 was changed from 0.689 mL to 0.295 mL, the amount of solution 2 was changed to 0.444 mL, the amount of DMAP solution was changed to 0.022 mL, the amount of EDC was changed to 0.039 mL, and 0.261 mL of solution 9 was further added, to obtain biodegradable film 10 and acetonitrile-containing film 10.
  • Biodegradable film 10 and acetonitrile-containing film 10 were evaluated in the same manner as in Example 1. The results are shown in Table 1.
  • biodegradable film 10 had a high compressive load and a high recovery rate.
  • Acetonitrile-containing film 10 had a high complex elastic modulus, and a short gelation time.
  • Example 2 The same operation as in Example 1 was carried out except that 10.0 g of branched polymer a1 was changed to 8-branched PEG (SUNBRIGHT (registered trademark) HGEO20000; manufactured by NiGK Corporation) to obtain purified multivalent compound A6.
  • the weight average molecular weight of the purified multivalent compound A6 as measured by GPC method was 26,600.
  • Example 1 The same operation as in Example 1 was carried out except that 10.0 g of water soluble polymer b1 was changed to 8-branched PEG (SUNBRIGHT (registered trademark) HGEO20000; manufactured by NiGK Corporation) to obtain purified multivalent compound B4.
  • the weight average molecular weight of the purified multivalent compound B4 as measured by GPC method was 20,800.
  • Example 1 The same operation as in Example 1 was carried out except that purified multivalent compound A6 was used instead of purified multivalent compound A1 to obtain solution 10. The same operation as in Example 1 was carried out except that purified multivalent compound B4 was used instead of purified multivalent compound B1 to obtain solution 11.
  • Example 2 The same operation as in Example 1 was carried out except that 0.689 mL of solution 1 was changed to 0.390 mL of solution 10, 0.311 mL of solution 2 was changed to 0.610 mL of solution 11, the amount of DMAP solution was changed to 0.009 mL, and the amount of EDC was changed to 0.015 mL, to obtain biodegradable film 11 and acetonitrile-containing film 11.
  • biodegradable film 11 had a high compressive load and a high recovery rate.
  • Acetonitrile-containing film 11 had a high complex elastic modulus, and a short gelation time.
  • Example 2 The same operation as in Example 1 was carried out except that anhydrous maleic acid (manufactured by Wako Pure Chemical Industries, Ltd.) was used instead of polycarboxylic acid b2 to obtain purified multivalent compound B5.
  • the weight average molecular weight of the purified multivalent compound B5 as measured by GPC method was 5,800.
  • the same operation as in Example 1 was carried out except that purified multivalent compound B5 was used instead of purified multivalent compound B1 to obtain solution 12.
  • Example 2 The same operation as in Example 1 was carried out except that the amount of solution 1 was changed to 0.570 mL, 0.311 mL of solution 2 was changed to 0.430 mL of solution 12, the amount of DMAP solution was changed to 0.022 mL, and the amount of EDC was changed to 0.038mL, to obtain biodegradable film 12 and acetonitrile-containing film 12.
  • Biodegradable film 12 and acetonitrile-containing film 12 were evaluated in the same manner as in Example 1. The results are shown in Table 1.
  • biodegradable film 12 had a high compressive load and a high recovery rate.
  • Acetonitrile-containing film 12 had a high complex elastic modulus, and a short gelation time.
  • Example 2 The same operation as in Example 1 was carried out except that 0.689 mL of solution 1 was changed to 0.633 mL of solution 7, 0.311 mL of solution 2 was changed to 0.367 mL of solution 8, the amount of DMAP solution was changed to 0.010 mL, and the amount of EDC was changed to 0.017 mL, to obtain biodegradable film 13 and acetonitrile-containing film 13.
  • Biodegradable film 13 and acetonitrile-containing film 13 were evaluated in the same manner as in Example 1. The results are shown in Table 1.
  • biodegradable film 13 had a low compressive load and a low recovery rate.
  • Acetonitrile-containing film 13 had a short gelation time and a low complex elastic modulus.
  • Example 2 The same operation as in Example 1 was carried out except that 0.689 mL of solution 1 was changed to 0.256 mL of solution 7, 0.311 mL of solution 2 was changed to 0.744 mL of solution 8, the amount of DMAP solution was changed to 0.020 mL, and the amount of EDC was changed to 0.035 mL, to obtain biodegradable film 14 and acetonitrile-containing film 14.
  • Biodegradable film 14 and acetonitrile-containing film 14 were evaluated in the same manner as in Example 1. The results are shown in Table 1.
  • biodegradable film 14 had a high compressive load and a low recovery rate.
  • Acetonitrile-containing film 14 had a high complex elastic modulus, and a short gelation time.
  • biodegradable film 15 had a high compressive load and a low recovery rate.
  • Acetonitrile-containing film 15 had a high complex elastic modulus, and a short gelation time.
  • Example 2 The same operation as in Example 1 was carried out except that 0.689 mL of solution 1 was changed to 0.204 mL of solution 10, 0.311 mL of solution 2 was changed to 0.796 mL of solution 11, the amount of DMAP solution was changed to 0.011 mL, and the amount of EDC was changed to 0.020 mL, to obtain biodegradable film 16 and acetonitrile-containing film 16.
  • Biodegradable film 16 and acetonitrile-containing film 16 were evaluated in the same manner as in Example 1. The results are shown in Table 1.
  • biodegradable film 16 had a high compressive load and a low recovery rate.
  • Acetonitrile-containing film 16 had a high complex elastic modulus and a short gelation time.
  • Example 2 The same operation as in Example 1 was carried out except that 0.689 mL of solution 1 was changed to 0.655 mL of solution 5, 0.311 mL of solution 2 was changed to 0.345 mL of solution 6, the amount of DMAP solution was changed to 0.009 mL, and the amount of EDC was changed to 0.016 mL, to obtain biodegradable film 17 and acetonitrile-containing film 17.
  • Biodegradable film 17 and acetonitrile-containing film 17 were evaluated in the same manner as in Example 1. The results are shown in Table 1.
  • biodegradable film 17 had a high recovery rate and a low compressive load.
  • Acetonitrile-containing film 17 had a short gelation time and a low complex elastic modulus.
  • Example 2 The same operation as in Example 1 was carried out except that 0.689 mL of solution 1 was changed to 0.275 mL of solution 5, 0.311 mL of solution 2 was changed to 0.725 mL of solution 6, the amount of DMAP solution was changed to 0.020 mL, and the amount of EDC was changed to 0.034 mL, to obtain biodegradable film 18 and acetonitrile-containing film 18.
  • Biodegradable film 18 and acetonitrile-containing film 18 were evaluated in the same manner as in Example 1. The results are shown in Table 1.
  • biodegradable film 18 had a high recovery rate and a low compressive load.
  • Acetonitrile-containing film 18 had a short gelation time and a low complex elastic modulus.
  • Example 1 8 5000 PLA 8 5000 succinic acid 1.2 28 105 400 85
  • Example 2 8 5000 PLA 8 5000 succinic acid 2.0 56 169 250 88
  • Example 3 8 5000 PLA 8 5000 succinic acid 4.0 35 91 180 86
  • Example 5 8 5000
  • the biodegradable material of the present invention can be used in the field of medicine, in applications for vascular embolization, adhesion-prevention, wound dressing, hemostasis, urinary incontinence-prevention or the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Polyesters Or Polycarbonates (AREA)

Claims (13)

  1. Biologisch abbaubares Material, das ein chemisch vernetztes Produkt zwischen einer multivalenten Verbindung A, die 3 oder mehr funktionelle Gruppen X aufweist, die aus der Gruppe ausgewählt sind, bestehend aus Hydroxylgruppe, Thiolgruppe und Aminogruppe; und einer multivalenten Verbindung B umfasst, die 3 oder mehr funktionelle Gruppen Y aufweist, die aus der Gruppe ausgewählt sind, bestehend aus Carboxylgruppe, Isocyanatgruppe und Thioisocyanatgruppe, wobei die chemische(n) Vernetzung(en) durch eine Kondensationsreaktion von der funktionellen Gruppe(n) X und der funktionellen Gruppe(n) Y gebildet wird/werden;
    wobei der Wert (y + z)/(x + z) 1,2 bis 4,0 beträgt, wenn MA ≥ MB, und der Wert (x + z)/(y + z) 1,2 bis 4,0 beträgt, wenn MA < MB;
    wobei x die Anzahl der funktionellen Gruppe(n) X repräsentiert, die nicht mit der funktionellen Gruppe(n) Y kondensiert ist/sind; wobei y die Anzahl der funktionellen Gruppe(n) Y repräsentiert, die nicht mit der funktionellen Gruppe(n) X kondensiert ist/sind; z die Anzahl der Vernetzung(en) repräsentiert; MA das Gewichtsmittel des Molekulargewichts von der multivalenten Verbindung A repräsentiert; und MB das Gewichtsmittel des Molekulargewichts von der multivalenten Verbindung B repräsentiert.
  2. Biologisch abbaubares Material nach Anspruch 1, wobei die multivalente Verbindung A eine der folgenden a) bis e) ist:
    a) ein Homopolymer oder ein Copolymer aus einem Monomer(en) aus einem wasserlöslichen Polymer(en), ausgewählt aus der Gruppe, bestehend aus Polyethylenglycol, Polypropylenglycol, Polyvinylalkohol, Polyhydroxyethylacrylat, Polyhydroxyethylmethacrylat, Carboxymethyl-cellulose, Hydroxymethylcellulose und Hydroxyethylcellulose;
    b) ein Copolymer aus dem Monomer aus dem wasserlöslichen Polymer und einem Monomer(en) aus einem hydrophoben Polymer(en), ausgewählt aus der Gruppe, bestehend aus Vinylacetat und Vinylcaprolactam;
    c) einem Copolymer aus dem Monomer aus dem wasserlöslichen Polymer und einer Hydroxycarbonsäure(n);
    d) ein verzweigtes Polymer, das gebildet wird, indem alle Hydroxylgruppen von einem Polyol mit einem Homopolymer oder einem Copolymer aus einem Monomer(en) aus einem wasserlöslichen Polymer(en), ausgewählt aus der Gruppe, bestehend aus Polyethylenglycol und Polypropylenglycol, verbunden werden;
    e) ein Copolymer aus dem verzweigten Polymer und einer Hydroxycarbonsäure(n).
  3. Biologisch abbaubares Material nach Anspruch 1 oder 2, wobei die multivalente Verbindung B eine der folgenden f) bis i) ist:
    f) eine Verbindung, die gebildet wird, indem eine Hydroxylgruppe(n) von einem Homopolymer oder einem Copolymer aus einem Monomer(en) aus einem wasserlöslichen Polymer(en), ausgewählt aus der Gruppe, bestehend aus Polyethylenglycol, Polypropylenglycol, Polyvinylalkohol, Polyhydroxyethylacrylat, Polyhyd roxyethylmethacrylat, Carboxymethyl-cellulose, Hydroxymethylcellulose und Hydroxyethylcellulose, mit einer Polycarbonsäure(n) verbunden wird/werden;
    g) eine Verbindung, die gebildet wird, indem eine Hydroxylgruppe(n) von einem Copolymer aus dem Monomer aus dem wasserlöslichen Polymer und einer Hydroxycarbonsäure(n) mit einer Polycarbonsäure(n) verbunden wird/werden;
    h) eine Verbindung, die gebildet wird, indem eine Hydroxylgruppe(n) von einem verzweigten Polymer, das gebildet wird, indem alle Hydroxylgruppen von einem Polyol mit einem Homopolymer oder einem Copolymer aus einem Monomer(en) aus einem wasserlöslichen Polymer(en), ausgewählt aus der Gruppe, bestehend aus Polyethylenglycol und Polypropylenglycol, verbunden werden, mit einer Polycarbonsäure(n) verbunden wird/werden;
    i) eine Verbindung, die gebildet wird, indem eine Hydroxylgruppe(n) von einem Copolymer des verzweigten Polymers und einer Hydroxycarbonsäure(n) mit einer Polycarbonsäure(n) verbunden wird/werden.
  4. Biologisch abbaubares Material nach Anspruch 2 oder 3, wobei das verzweigte Polymer einen Verzweigungsgrad von 3 bis 16 aufweist.
  5. Biologisch abbaubares Material nach einem der Ansprüche 2 bis 4, wobei das Polyol aus der Gruppe ausgewählt ist, bestehend aus Glycerin, Polyglycerin und Pentaerythritol.
  6. Biologisch abbaubares Material nach einem der Ansprüche 2 bis 5, wobei die Hydroxycarbonsäure(n) aus der Gruppe ausgewählt ist/sind, bestehend aus Glycolsäure, Milchsäure, Glycerinsäure, Hydroxybuttersäure, Apfelsäure, Weinsäure, Hydroxyvaleriansäure, 3-Hydroxyhexansäure und 6-Hydroxycapronsäure.
  7. biologisch abbaubares Material nach einem der Ansprüche 3 bis 6, wobei die Polycarbonsäure(n) aus der Gruppe ausgewählt ist/sind, bestehend aus Oxalsäure, Malonsäure, Bernsteinsäure, Glutarsäure, Adipinsäure, Pimellinsäure, Korksäure, Azelainsäure, Sebacinsäure, Apfelsäure, Weinsäure und Fumarsäure.
  8. Gefäßembolisierungsmaterial, das aus dem biologisch abbaubaren Material nach einem der Ansprüche 1 bis 7 gebildet ist.
  9. Antihaftmaterial, das aus dem biologisch abbaubaren Material nach einem der Ansprüche 1 bis 7 gebildet ist.
  10. Wundverbandmaterial, das aus dem biologisch abbaubaren Material nach einem der Ansprüche 1 bis 7 gebildet ist.
  11. Hämostatisches Material, das aus dem biologisch abbaubaren Material nach einem der Ansprüche 1 bis 7 gebildet ist.
  12. Harninkontinenzpräventionsmaterial, das aus dem biologisch abbaubaren Material nach einem der Ansprüche 1 bis 7 gebildet ist.
  13. Verfahren zum Herstellen eines biologisch abbaubaren Materials, wobei das Verfahren einen chemischen Vernetzungsschritt umfasst, wobei eine multivalente Verbindung A, die 3 oder mehr funktionelle Gruppen X aufweist, die aus der Gruppe ausgewählt sind, bestehend aus Hydroxylgruppe, Thiolgruppe und Aminogruppe, und eine multivalente Verbindung B, die 3 oder mehr funktionelle Gruppen Y aufweist, die aus der Gruppe ausgewählt sind, bestehend aus Carboxylgruppe, Isocyanatgruppe und Thioisocyanatgruppe, in einem Lösungsmittel gelöst werden, um der chemischen Vernetzungsreaktion zu ermöglichen so abzulaufen, dass der Wert NB/NA 1,2 bis 4,0 beträgt, wenn MA ≥ MB, und der Wert NA/NB 1,2 bis 4,0 beträgt, wenn MA < MB; wobei NA die Gesamtzahl der funktionellen Gruppen X repräsentiert; NB die Gesamtzahl der funktionellen Gruppen Y repräsentiert; MA das Gewichtsmittel des Molekulargewichts von der multivalenten Verbindung A repräsentiert; und MB das Gewichtsmittel des Molekulargewichts von der multivalenten Verbindung B repräsentiert, um das biologisch abbaubare Material zu erhalten.
EP13768529.3A 2012-03-28 2013-03-28 Biologisch abbaubares material und verfahren zur herstellung von biologisch abbaubarem material Not-in-force EP2832380B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012073776 2012-03-28
PCT/JP2013/059209 WO2013146998A1 (ja) 2012-03-28 2013-03-28 生分解性材料及び生分解性材料の製造方法

Publications (3)

Publication Number Publication Date
EP2832380A1 EP2832380A1 (de) 2015-02-04
EP2832380A4 EP2832380A4 (de) 2015-11-04
EP2832380B1 true EP2832380B1 (de) 2016-11-30

Family

ID=49260246

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13768529.3A Not-in-force EP2832380B1 (de) 2012-03-28 2013-03-28 Biologisch abbaubares material und verfahren zur herstellung von biologisch abbaubarem material

Country Status (9)

Country Link
US (1) US9393340B2 (de)
EP (1) EP2832380B1 (de)
JP (1) JP6191456B2 (de)
CN (1) CN104185480B (de)
CA (1) CA2866281C (de)
ES (1) ES2613484T3 (de)
PT (1) PT2832380T (de)
RU (1) RU2572849C1 (de)
WO (1) WO2013146998A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020202210A1 (en) * 2019-04-03 2020-10-08 Sree Chitra Tirunal Institute For Medical Sciences And Technology A radiopaque polymeric liquid embolic system

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102448320B1 (ko) * 2016-09-30 2022-09-30 나노시타 가부시키가이샤 유착 방지재
CN109232838B (zh) * 2018-08-06 2021-04-06 浙江工业大学 一种新型可生物降解的快速光固化成型材料的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
DE3246616A1 (de) * 1982-12-16 1984-06-20 Henkel KGaA, 4000 Düsseldorf Polyol modifizierte alkydharze zur verwendung in wasserlacken
US5093319A (en) 1989-10-31 1992-03-03 Pfizer Hospital Products Group, Inc. Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions
ES2066152T3 (es) 1989-10-31 1995-03-01 Howmedica Composiciones que contienen derivados de la quitina para impedir la adhesion.
ATE130517T1 (de) 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
JP3120187B2 (ja) 1990-08-08 2000-12-25 武田薬品工業株式会社 血管新生阻害物質を含む血管内塞栓剤
WO1996021056A1 (fr) 1995-01-04 1996-07-11 Mitsubishi Chemical Corporation Fibre, film, suture chirurgicale bioabsorbable et inhibiteur d'adhesion bioabsorbable comportant chacun un copolymere sequence biocompatible
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
RU2073529C1 (ru) * 1995-05-16 1997-02-20 Центральный научно-исследовательский рентгенорадиологический институт Композиция для эмболизации кровеносных сосудов
US8003705B2 (en) * 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
JP3483753B2 (ja) 1997-12-29 2004-01-06 タキロン株式会社 生体内分解吸収性可塑性粘着物
US6312725B1 (en) 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
CA2407235A1 (en) 2000-04-28 2001-11-08 Fziomed, Inc. Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use
JP4734772B2 (ja) 2001-06-13 2011-07-27 日油株式会社 ポリマー、生体内吸収性材料および組織癒着防止膜
JP2003252936A (ja) 2002-02-28 2003-09-10 Sentomedo:Kk 温度応答性材料及びそれを含む組成物
EP1559440B1 (de) 2002-10-29 2015-09-23 Toray Industries, Inc. Gefässembolisationsmaterial
JP4686970B2 (ja) 2002-10-29 2011-05-25 東レ株式会社 血管塞栓材料
DE602004016161D1 (de) 2003-07-07 2008-10-09 Nof Corp Triblock-copolymer, herstellungsverfahren dafür und biokompatibles material
JP4655505B2 (ja) 2004-04-28 2011-03-23 東レ株式会社 架橋生分解性粒子およびその製造方法
JP4442302B2 (ja) 2004-04-28 2010-03-31 東レ株式会社 生分解性粒子
CN102432986B (zh) 2005-10-27 2014-12-10 东丽株式会社 生物降解性粒子
JP5223182B2 (ja) 2005-10-27 2013-06-26 東レ株式会社 生分解性粒子およびその製造方法
JP5398112B2 (ja) 2005-10-27 2014-01-29 東レ株式会社 生分解性粒子およびその製造方法
JP5217149B2 (ja) 2006-03-31 2013-06-19 東レ株式会社 生分解性球状粒子
JP5209192B2 (ja) 2006-08-07 2013-06-12 東洋紡株式会社 生体適合性多孔質シートおよびそれを用いた人工皮膚
RU61120U1 (ru) * 2006-10-13 2007-02-27 Закрытое акционерное общество "ААА-КОМПАНИ" Средство для эмболизации сосудов
US8246998B2 (en) 2007-11-01 2012-08-21 Boston Scientific Scimed, Inc. Injectable biodegradable particles
CN101240116B (zh) * 2008-02-18 2011-03-30 西南交通大学 一种具有形状记忆功能的可生物降解高分子复合材料及其制备方法和用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020202210A1 (en) * 2019-04-03 2020-10-08 Sree Chitra Tirunal Institute For Medical Sciences And Technology A radiopaque polymeric liquid embolic system
US11986571B2 (en) 2019-04-03 2024-05-21 Sree Chitra Tirunal Institute For Medical Sciences And Technology Radiopaque polymeric liquid embolic system

Also Published As

Publication number Publication date
WO2013146998A1 (ja) 2013-10-03
CN104185480B (zh) 2016-04-20
EP2832380A4 (de) 2015-11-04
ES2613484T3 (es) 2017-05-24
JPWO2013146998A1 (ja) 2015-12-14
RU2572849C1 (ru) 2016-01-20
US20150045518A1 (en) 2015-02-12
CA2866281A1 (en) 2013-10-03
CN104185480A (zh) 2014-12-03
US9393340B2 (en) 2016-07-19
PT2832380T (pt) 2017-01-24
JP6191456B2 (ja) 2017-09-06
CA2866281C (en) 2016-11-01
EP2832380A1 (de) 2015-02-04

Similar Documents

Publication Publication Date Title
EP2832381B1 (de) Biologisch abbaubares material und verfahren zur herstellung von biologisch abbaubarem material
CA2831414C (en) Biodegradable particle, vascular embolization material and method for producing biodegradable particles
EP2832380B1 (de) Biologisch abbaubares material und verfahren zur herstellung von biologisch abbaubarem material
EP2650026B1 (de) Biologisch abbaubare partikel, gefässverschlussmaterial und verfahren zur herstellung biologisch abbaubarer partikel
EP2656864B1 (de) Biologisch abbaubare partikel zur medizinischen behandlung und gefässembolisierungsmaterial
RU2588222C2 (ru) Биоразрушаемый материал и способ получения биоразрушаемого материала
Jiang et al. Modification of poly (L-lactic acid) with L-lactic acid/citric acid oligomers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140905

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151002

RIC1 Information provided on ipc code assigned before grant

Ipc: C08G 63/06 20060101ALI20150928BHEP

Ipc: A61L 17/00 20060101ALI20150928BHEP

Ipc: A61L 31/00 20060101AFI20150928BHEP

Ipc: C08L 101/16 20060101ALI20150928BHEP

Ipc: A61L 15/64 20060101ALI20150928BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602013014806

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61L0031000000

Ipc: A61L0031140000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C08G 63/08 20060101ALI20160531BHEP

Ipc: C08G 63/668 20060101ALI20160531BHEP

Ipc: A61L 15/64 20060101ALI20160531BHEP

Ipc: C08L 101/16 20060101ALI20160531BHEP

Ipc: A61L 31/14 20060101AFI20160531BHEP

Ipc: A61L 24/00 20060101ALI20160531BHEP

Ipc: C08L 67/02 20060101ALI20160531BHEP

Ipc: C08L 67/04 20060101ALI20160531BHEP

INTG Intention to grant announced

Effective date: 20160706

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 849212

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013014806

Country of ref document: DE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2832380

Country of ref document: PT

Date of ref document: 20170124

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20170113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20161130

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 849212

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170228

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2613484

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170228

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013014806

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26N No opposition filed

Effective date: 20170831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170328

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170328

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170331

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20180321

Year of fee payment: 6

Ref country code: PT

Payment date: 20180328

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20180404

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20200317

Year of fee payment: 8

Ref country code: GB

Payment date: 20200318

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20200214

Year of fee payment: 8

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20200728

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161130

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190329

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602013014806

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210331

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210328

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211001